|
|
|
|
|
13.01.26 - 14:03
|
CytoMed Therapeutics′ new year update and seeks shareholders′ feedback on proposal to improve shareholder value for their patient capital (GlobeNewswire EN)
|
|
|
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will enhance access to rare and valuable cord blood as sources for cell-based allogeneic therapies. In addition to CytoMed's gamma delta T cells, Natural Killer cells also express receptors that recognise stress ligands, allowing them to be cytotoxic tools to combat a wide variety of solid and hematological cancer...
|
|
|
13.01.26 - 14:03
|
Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines (Business Wire)
|
|
|
NEW YORK & BOSTON--(BUSINESS WIRE)--#AI--Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, today announced an oversubscribed $80M seed financing. The round was led by DCVC, with participation from NVentures (NVIDIA's venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures, and additional strategic and institutional investors.
As part of the financing, the company has rebranded from VantAI to Proxima to reflect its singular focus on building out both the technology and data layer needed to unlock proximity-based therapeutics. These next generation medicines work by controlling how proteins interact with one another, rather than simply inhibiting or activating a single target, and represent a superset that includes modalities such as molecular glues and PROTACs that have the potential to unlock historically undruggable disease targets.
The ...
|
|
|
|
|
13.01.26 - 12:00
|
SciNeuro and Novartis sign global licensing deal for Alzheimer′s antibody (PBR)
|
|
|
The agreement will leverage SciNeuro's proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies
The post SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody appeared first on Pharmaceutical Business review....
|
|
|
13.01.26 - 09:15
|
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders. This milestone triggers a payment of US$3.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognised as revenue in Q4 FY2025....
|
|
|
|
|
13.01.26 - 08:15
|
Research: Daiwa Raises WUXI BIO TP to $42, Keeps Buy Rating (AAStocks)
|
|
|
Daiwa released a research report raising its target price for WUXI BIO (02269.HK) from $35.5 to $42, with rating kept at Buy. The broker lifted its 2025-2027 EPS forecasts for WUXI BIO by 1-5%, based on higher project signing expectations and continued operational leverage, and raised its 2028-2032 revenue forecasts by 3-7%, bas......
|
|
|
|
|
|
|
13.01.26 - 05:45
|
Research: CMBI Ratings, TPs on Pharma (Table) (AAStocks)
|
|
|
Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 SINO BIOPHARM(01177.HK) | Buy | 9.4 WUXI XDC(02268.HK) | Buy | 74 ~AAStocks Financial NewsWeb Site: www.aastocks.com...
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 05:00
|
Research: M Stanley's Latest HK Stock Focus List (Table) (AAStocks)
|
|
|
Stock | Potential Upside to Target PriceAlibaba (BABA.US) | 16.5%YANGTZE POWER (600900.SH) | 27.6%CONTEMPORARY AMPEREX (300750.SZ) | 32.7%DUALITYBIO-B (09606.HK) | 39.3%ESPRESSIF (688018.SH) | 26.9%HKEX (00388.HK) | 19.5%HKT-SS (06823.HK) | 10.7%NARI (600406.SH) | 12.3%PING AN (02318.HK) | 26.8%INOVANCE TECH (300124.SZ) | 22.5%S......
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
